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A B S T R A C T
Increasingly, the effectiveness of adjuvant chemotherapy agents for breast cancer has been
related to changes in the genomic profile of tumors. We investigated correspondence be-
tween growth inhibitory concentrations of paclitaxel and gemcitabine (GI50) and gene
copy number, mutation, and expression first in breast cancer cell lines and then in patients.
Genes encoding direct targets of these drugs,metabolizing enzymes, transporters, and those
previously associated with chemoresistance to paclitaxel (n ¼ 31 genes) or gemcitabine
(n ¼ 18) were analyzed. A multi-factorial, principal component analysis (MFA) indicated
expression was the strongest indicator of sensitivity for paclitaxel, and copy number and
expressionwere informative for gemcitabine. The factorswere combined using support vec-
tor machines (SVM). Expression of 15 genes (ABCC10, BCL2, BCL2L1, BIRC5, BMF, FGF2, FN1,
MAP4,MAPT,NFKB2, SLCO1B3, TLR6, TMEM243, TWIST1, and CSAG2) predicted cell line sensi-
tivity to paclitaxelwith 82%accuracy. Copynumber profiles of 3 genes (ABCC10,NT5C,TYMS )
togetherwith expressionof 7 genes (ABCB1,ABCC10,CMPK1,DCTD,NME1,RRM1,RRM2B), pre-
dicted gemcitabine responsewith 85% accuracy. Expression and copy number studies of two
independent sets of patients with known responses were then analyzed with these models.
These included tumor blocks from 21 patients that were treated with both paclitaxel and
gemcitabine, and 319 patients on paclitaxel and anthracycline therapy. A new paclitaxel
SVM was derived from an 11-gene subset since data for 4 of the original genes was
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unavailable. The accuracy of this SVM was similar in cell lines and tumor blocks (70e71%).
ThegemcitabineSVMexhibited62%predictionaccuracy for the tumorblocksdue to thepres-
ence of samples with poor nucleic acid integrity. Nevertheless, the paclitaxel SVM predicted
sensitivity in 84% of patients with no or minimal residual disease.
ª 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.
1. Introduction
Chemotherapeutic agents, such as paclitaxel and gemcita-
bine, are recommended to patients with developed metasta-
ses, basal-like breast cancer, and high-risk indications
(premenopausal, ER/PR-negative, HER2-status, large tumors,
or node-positive) (Cardoso et al., 2012; Oostendorp et al.,
2011). There is currently no gold standard chemotherapy
regimen (Cardoso et al., 2012; Oostendorp et al., 2011). Treat-
ment selection is suggested to be individualized and should
take into account clinical disease characteristics, treatment
history, patient-related factors, and patient preference.
However, resistance is one of themajor barriers to successful
therapy. In a recent study, breast cancer patient response
rates to paclitaxel and gemcitabine after 6 cycles of chemo-
therapy were found to be only 50.0% and 78.6% respectively
(Lee et al., 2014). This has motivated a number of groups to
develop gene signatures aimed at predicting therapeutic
response to these drugs in breast cancer patients
(Ga˛sowska-Bodnar et al., 2014; Hatzis et al., 2011; He et al.,
2014).
As in breast cancer patients, breast cancer cell lines show
variable responses to growth inhibition by paclitaxel and
gemcitabine (Daemen et al., 2013; Shoemaker, 2006). Cell
lines mirror many of the pathological features of breast tu-
mors, such as the intrinsic subtypes of breast cancer (Neve
et al., 2006; Prat et al., 2013), and can be useful for testing
anticancer therapy responses (Heiser et al., 2012). Daemen
et al. (2013) employed random forest machine learning to
assess genomic information from 70 breast cancer cell lines
(including DNA sequence, gene copy number, gene expres-
sion, promoter methylation, protein expression, and the cor-
responding cell line response to 90 anti-cancer compounds)
with the objective of establishing pretreatment signatures
that predict response. The gene expression profile of the tu-
mor subtype was found to be themost effective way tomodel
response to therapy. However, many molecular signatures
derived using genome-wide approaches are inconsistent be-
tween different data sets (Ein-Dor et al., 2006; Nilsson et al.,
2009). This is partly due to the fact that deriving predictive
gene models using thousands of genes risks overtraining,
that is, fitting the noise rather than the actual gene signature
in the data (Ein-Dor et al., 2006).
We recently defined a set of genes that are stable in gene
expression and copy number in the majority (>90%) of breast
cancer tumors (Park et al., 2012). The stable gene set is
composed of genes that are unmutated in the majority of tu-
mors. Interestingly, many stable gene products were found
to be targets of paclitaxel and gemcitabine. We examine the
possibility that genomic differences in expression, copy
number or mutation in these genes may be related to GI50.
Rather than a genome-wide approach to predict sensitivity
to paclitaxel and gemcitabine (eg. employed by Daemen
et al. (2013)), we analyze stable and linked unstable genes in
pathways that determine their disposition (Figure 1).
Figure 1 e Workflow to derive gene signatures. Gene sets were
derived for paclitaxel and gemcitabine based on known drug
pathways, metabolism, and genes previously implicated in resistance.
A multiple factor analysis was completed for each gene to determine
which data types (gene expression, copy number, and mutation data)
were correlated with the growth inhibitory values for paclitaxel and
gemcitabine. Gene expression values were used to derive the paclitaxel
SVM classifier, and both gene expression and copy number were used
for the gemcitabine SVM. Cell lines were then clustered on optimized
gene sets to visualize stratification of tumor subtype and sensitivity.
The SVM classifiers were validated using random gene iterations to
determine the significance of the classification accuracy, and patient
data sets to ensure robustness of the models derived.
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Gene panels were established based on biological and
experimental studies of paclitaxel and gemcitabine meta-
bolism. Paclitaxel binds to the b subunit of tubulin (TUBB1),
inhibiting microtubule formation during mitosis (Jordan and
Wilson, 2004). It also binds BCL2, which induces programmed
cell death (Ferlini et al., 2009). Paclitaxel is now also recog-
nized to target microtubule-associated proteins 2 (MAP2), 4
(MAP4) and Tau (MAPT ) (McGrogan et al., 2008), as well as
the xenobiotic receptor (NRI12, or PXR) (Harmsen et al.,
2009). SLCO1B3 transports paclitaxel into cells (Smith et al.,
2005), and it is exported by ABCB1 (P-glycoprotein), multidrug
resistance-associated proteins ABCC1 (Heijn et al., 1997) and
ABCC10 (Chen et al., 2003), and the bile salt export pump
ABCB11 (Lecureur et al., 2000). Other genes previously impli-
cated as contributing to paclitaxel resistance include
TMEM243 (Duan et al., 2004), BCAP29 (Rao et al., 2008), GBP1
(Duan et al., 2006), TLR6 (Kaczanowska et al., 2013), NFKB2
(Tantivejkul et al., 2005), FGF2 (Carmo et al., 2011), BIRC5 (Lu
et al., 2009), TWIST1 (Hong et al., 2011), FN1 (Xing et al.,
2008), OPRK1 (Duan et al., 2005), CSAG2 (Duan et al., 1999),
and CNGA3 (Duan et al., 2005). Additionally, genes expressed
in breast tissue involved in paclitaxel metabolism were
included: CYP2C8 and CYP3A4 (Preissner et al., 2010), as well
as stable genes in pathways of known direct targets (Park
et al., 2012): BAD, BBC3, BCL2L1, BMF, TUBB4A (Kavallaris,
2010), and TUBB4B (Kavallaris, 2010).
Gemcitabine, a deoxycytidine analog, is transported into the
cell by SLC29A1 (Marce et al., 2006), SLC29A2, SLC28A1 (Mackey
et al., 1999), and SLC28A3 (Govindarajan et al., 2009). The pro-
drug is then phosphorylated byDCK, CMPK1, andNME1 to gem-
citabine diphosphate and triphosphate (Ueno et al., 2007).
These active forms are incorporated into DNA, which halts
replication and cell growth (Plunkett et al., 1995). Gemcitabine
di- and triphosphate target ribonucleotide reductase (RRM1,
RRM2, and RRM2B), and inhibit DNA synthesis (Mini et al.,
2006). An alternative metabolite, difluorodeoxyuridine mono-
phosphate, which is derived by cytidine deaminase (CDA) or
dCMP deaminase (DCTD), inhibits thymidylate synthetase
(TYMS ), resulting in apoptosis (Ueno et al., 2007).
We examine the hypothesis that genomic differences in ge-
notypes, expression and copy number of these genes explain
concentration-dependent growth inhibition by gemcitabine
and paclitaxel. We then use machine learning to stratify the
relative contributions of different genes to chemoresistance,
by identifying corresponding genomic signatures at the tran-
scriptional and genomic level in both cell line and patient data.
2. Materials and methods
2.1. Data acquisition
Growth inhibition (GI50), copy number, gene expression, and
exome sequencing data were obtained from the supplemen-
tary data of Daemen et al. (2013). GI50s (log10M, where M is
the drug concentration required to inhibit cell line growth by
50%) for paclitaxel were available for 49 cell lines and GI50s
for gemcitabine were available for 47 cell lines.
Supplementary Table 1 indicates the cell lines used and
Supplementary Table 2 indicates the gene, gene product names
and their respective drug disposition functions. Supplementary
Methods I & II describe copynumber and variant calling, results
of which are shown in Supplementary Tables 3 and 4. Log2
normalized gene expression data were derived from Affyme-
trix Gene Chip Human Exon 1.0 ST arrays. Replication studies
performed to re-measure and confirm GI50s, verify copy num-
ber andmutation data for a subset of the cell lines are outlined
in Supplementary Methods III. Figure 1 is an overview of the
complete workflow used.
2.2. Cell lines
Cell lines were composed of 10 basal, 9 claudin-low, 25
luminal, and 5 normal-like subtypes. Cell lines were desig-
nated resistant, if their GI50 was <8.0 for paclitaxel and <7.0
for gemcitabine, respectively. The threshold values for distin-
guishing sensitive from resistant cell lines were based on me-
dian GI50s for each particular drug (7.99 and 7.13, for
paclitaxel and gemcitabine). Daemen et al. (2013) classified
cell lines by comparing mean GI50s. We used median GI50,
which is not impacted to the same extent by outlier cell lines.
2.3. Multiple factor analysis (MFA)
MFA was used to relate each cell line GI50 according to sets of
genomic variables (Abdi and Valentin, 2007). The 44 (gemcita-
bine) or 45 (paclitaxel) breast cancer cell lines (Supplementary
Table 1) were treated as separate individuals. MFA was carried
out with the R library “FactoMineR” (Le^ et al., 2008), with GI50s,
geneexpression, copynumber,mutationstatus (if thegenecon-
tained 1 or more mutations), and 31 and 18 genes associated
with paclitaxel and gemcitabine activity, respectively, as input.
2.4. Support vector classification
A binary support vector machine (SVM) was trained with the
Statistics Toolbox inMATLAB (Natick,MA) using fitcsvm (linear
kernel function) and then tested with a leave-one-out cross-
validation (using ‘crossval’ and ‘leaveout’ options). The SVM
was trained on the cell lines and explanatory gene variables
deemed relevant from the MFA: expression data for the pacli-
taxel SVM, and copy number and expression data for the gem-
citabine SVM. The input data consisted of measurements from
all genes used in the MFA. Sequential backward feature selec-
tion was performed for feature optimization (Dash and Liu,
1997) to minimize the percentage of misclassified cell lines
(classification error) returned from the leave-one-out cross
validation (Supplementary Methods IV). Genes that did not
reduce or change the classification error were removed from
the SVM (one at a time). This procedure was iterated until
further gene removal lead to a higher classification error (stop-
ping criterion). The SVM used to analyze patient expression
and outcomes of paclitaxel treatment excluded 2 of the 49
cell lines (184A1 and 184B5) from the feature selection process
and the subsequent validation. This was done because these
lines were not derived from breast cancer tissue, but rather
normal tissue that was transformed by exposure to benzo(a)
pyrene. By contrast with the SVM, a partial-least squares
regression was not effective in relating genomic findings to
paclitaxel response (Supplementary Methods V).
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The hinge loss was also determined for the subset of genes
included in the final SVMs. Hinge loss applies a linear penalty
for misclassified data according to their distance from the hy-
perplane. The loss function is represented by Equation (1)
where yj ¼ {1,1} and f(Xj) is the score, i.e. hyperplane dis-
tance, for cell line j:
L ¼max

0; 1 yjf

Xj

(1)
2.5. Applying the cell line SVM to patient data
Formalin fixed, paraffin embedded (FFPE) tumor samples were
obtained from the Fondazione IRCCS Istituto Nazionale dei
Tumori (Milan, Italy), from leftover material available after
diagnostic procedures in consented patients (Musella et al.,
2015). Samples obtained were from patients that were first
treated with paclitaxel (or in a small number of cases doce-
taxel) and carboplatin, and then subsequently gemcitabine,
upon development of resistance. Clinical information was
available as to whether the patients responded to each of
the drugs (paclitaxel and gemcitabine). Tumor and control
normal tissues were analyzed for expression and copy num-
ber of SVM genes, respectively, by real-time reverse-transcrip-
tase polymerase chain reaction (qRT-PCR) and real time PCR
(qPCR, methods described in Supplementary Methods,
Section VI). The cell line-based SVMmodels were used to pre-
dict patient sample drug responses in a blinded manner. Two
SVMmodels were trained for paclitaxel and gemcitabine: one
using the normalized gene expression values, and the other
using expression values binned into 10 categories, using the
Matlab function: quantile(X,10). Binning was performed
because amplifiable RNA template concentration in FFPE
blocks is not known precisely, because it is subject to long
term degradation and reactivity (Antonov et al., 2005; Fleige
and Pfaffl, 2006). Expression measurements were obtained
for 11 genes from the paclitaxel SVM, and 6 genes for the gem-
citabine SVM. The SVM was trained on the cell line data with
these reduced gene sets. Predicted and actual responses were
compared, and odds risk ratios (contingency analysis) were
calculated (GraphPad Prism, San Diego, California).
Patient data were also obtained from GEO Accession
GSE25066, in which expression levels of tumors that were
treatedwith taxane and anthracycline chemotherapywere re-
ported (Hatzis et al., 2011). Expression levels for the paclitaxel
SVMgenes (except BMF and CSAG2, whichwere notmeasured)
were extracted for those patients treated with paclitaxel
(n ¼ 319). In cases with multiple probe sets per gene, expres-
sion levels were averaged. The SVM predictions were then
related to response to therapy and residual cancer burden
class for each patient.
2.6. Clustering cell lines and patients using expression
values of the SVM gene subsets
The unsupervised, hierarchical clustering function ‘cluster-
gram’ in Matlab was used to cluster cell lines and patient
data (described in 2.5) according to gene expression values
included in the optimized SVM. Expression values were
normalized by row so the mean expression of each gene
across individuals was 0, and the standard deviation was 1.
Clustering was performed by individuals and genes, and den-
drograms are displayed for each dimension that indicate
relatedness based on their lengths and hierachical branching.
3. Results
3.1. Multiple factor analysis
MFAs were performed using GI50s of 49 cell lines, and
genomic measurements of 31 and 18 genes related to pacli-
taxel and gemcitabine activity from an existing data set
(Daemen et al., 2013). We re-confirmed measurements for a
subset of the cell lines to ensure consistency between cell
line sources (see Supplementary Results I). MFAs were
assessed by statistics generated by the program, FactoMineR
(Le^ et al., 2008). Relationships were stratified by the correlation
between the variable and GI50, the RV coefficient (a multivar-
iate generalization of the squared Pearson correlation coeffi-
cient), the position of variables on the correlation circle, and
the representation quality of each variable group in the first
two dimensions (cos2 values). These criteria were used to
classify each gene as having a “strong relationship”, “relation-
ship”, “possible relationship” or “no relationship” to GI50 (see
Supplementary Table 5 for the thresholds for each class). Ex-
amples of correlation circles and individual factor maps for
MAPT (paclitaxel) and DCTD (gemcitabine) are illustrated in
Supplementary Results II.
MFA revealed “strong relationships” between paclitaxel
GI50 and copy number and/or gene expression for 11 genes,
consisting of both negative relationships (diminished copy
numberandgeneexpression [-] forCYP2C8,CYP3A4,NR1I2 (pre-
viously known as PXR), TLR6, and TUBB1) and positive relation-
ships (increasedcopynumberandgeneexpression [þ] forBBC3,
BCL2L1, BMF, CNGA3, MAPT, and TUBB4B) with increased che-
moresistance (Supplementary Table 6 lists all MFA measure-
ments). The gemcitabine set revealed strong associations
between resistance and ABCB1 (þ), DCTD (), and SLC28A1 (þ)
gene expression as well as strong relationships for ABCC10 (þ)
and CDA (þ) copy number (Supplementary Table 7). The MFA
results for paclitaxel (gene expression results only) and gemci-
tabine treatment (copy number and gene expression), in the
respective pathway contexts, are summarized in Figure 2.
Point mutation status was based on 74 deleterious coding
mutations (Supplementary Table 4) that were predicted to be
damaging (Ng and Henikoff, 2003) or to affect mRNA splicing
(Shirley et al., 2013; Viner et al., 2014). Point mutations pre-
dicted to be damaging demonstrated strong relationships in
ABCB1 (n ¼ 4, in 2 cell lines) to paclitaxel resistance and in
SLC28A3 (n ¼ 3, in 2 cell lines) to increased sensitivity to gem-
citabine. The limited number of cell lines with mutations in
these genes cannot be effectively incorporated into machine
learning models, and point mutation results were not
included in these analyses.
3.2. Support vector machine (SVM) learning
A binary SVMwas employed to develop a predictive multigene
classification of genomic signatures for resistance to these
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Figure 2 e Genes associated with paclitaxel (A) and gemcitabine (B) mechanism of action (direct targets, metabolizing enzymes), genes previously
associated with resistance, and stable genes in the biological pathways targets. Genes with an asterisk (*) are stable genes (Park et al., 2012). Genes
highlighted in red showed a positive correlation (within dimension 1 and/or dimension 2) between gene expression or copy number, and resistance
in the MFA, whereas genes highlighted in blue demonstrated a negative correlation. Genes outlined in dark grey are those included in the final
predictive model that was derived using the SVM. Red T-shaped bars indicate the genes that paclitaxel directly binds/inhibits. Genes outlined in
light grey (ie. BAX/BAK) were not included in the analysis because they were not stable genes in the BCL2 pathway.
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drugs (Furey et al., 2000). Based on MFA results, data types
orthogonal to GI50 were excluded from the SVM (see section
2.4 for details). The classification error of the SVM model was
minimized by removing genes, i.e. features, which did not
improve accuracy by leave-one-out cross-validation. This
feature selection process is illustrated in Figure 3-I. The opti-
mized SVMwas then trained, respectively, on 15 gene variables
for paclitaxel (49 cell lines) and 10 variables for gemcitabine
(44 cell lines). Gene expression values from ABCC10, BCL2,
BCL2L1, BIRC5, BMF, FGF2, FN1, MAP4, MAPT, NFKB2, SLCO1B3,
TLR6, TMEM243, TWIST1, and CSAG2 comprised the final set
of features used to train the SVM for classification of paclitaxel
sensitivity. For gemcitabine, both gene expression values (from
ABCB1, ABCC10, CMPK1, DCTD, NME1, RRM1, RRM2B) and copy
number data (fromABCC10,NT5C, TYMS ) were used in the final
SVM. The distance of each cell line value from the SVM hyper-
plane that distinguishes the degree of sensitivity or resistance
was plotted against the corresponding GI50 (Supplementary
Results III). The trained SVMs misclassified 9 of 49 (18%) cell
lines for paclitaxel and 7 of 44 (16%) for gemcitabine, which is
comparable to or more accurate than other approaches (Ma
et al., 2004, demonstrated 19%misclassification for tamoxifen).
Partitioning by histological subtype did not improve the classi-
fication accuracy; a single variable SVM model based on sub-
type misclassified 30% of cell lines for paclitaxel and 45% for
gemcitabine (Supplementary Table 8). The feature-optimized
SVM outperformed the signature derived from the initial set
of genes, which misclassified resistance/sensitivity of 36%
cell lines for paclitaxel and 64% for gemcitabine treatments.
In addition, multi-gene MFA analyses of the final SVM gene
sets demonstrate that the individual factor maps of the resis-
tant and sensitive cell lines segregate to a greater degree than
MFAs based on the initial gene sets, which were indistinguish-
able (Supplementary Results IV). These differences were larger
for gemcitabine than paclitaxel.
To assess the individual impacts of a gene on SVM accu-
racy, each gene remaining in the optimized SVM was
removed, and the misclassification rate was redetermined
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Figure 3 e Effect of the removal of each gene on the percent of cell lines misclassified during the SVM feature selection process to determine the
most predictive gene set (left panels AI and BI). The right panels (AII and BII) demonstrate the increase in the percent of cell lines misclassified
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(Figure 3A-II). BCL2L1 and MAPT had the highest predictive
value for paclitaxel sensitivity, with misclassification rates
of 36% and 34%, respectively, when eliminated (compared to
21e30% for the other genes). It is notable that the MFA also
showed strong associations with decreasing MAPT or BLC2L1
expression and increasing paclitaxel sensitivity. BCL2L1 is a
member of the Bcl-2 family and is involved in regulation of
apoptosis (Ferlini et al., 2009). Additional apoptotic regulators,
such as BMF and BCL2, also appear in our SVM results, as pacli-
taxel is known to trigger apoptosis through these pathways
(Kutuk and Letai, 2008). The loss ofMAPT in breast cancer cells
has been shown to sensitize those cells to the action of pacli-
taxel (Bhat and Setaluri, 2007), which is supported by our
analysis.
For gemcitabine, removing NT5C copy number, NME1 gene
expression, ABCC10 gene expression, and RRM2B gene expres-
sion had the largest effects, by respectively increasing
misclassification rates to 34%, 32%, 32%, and 30% (Figure 3B-
II). NT5C is located on 17q25.1 a region associated with cancer
(Fukino et al., 1999). Allelic imbalances in TYMS have previ-
ously been hypothesized to be involved in drug resistance in
renal cell carcinoma (Colavito et al., 2009) and ABCC10 has
been associated with drug resistance (Hopper-Borge et al.,
2009). NME1 is a known metastasis suppressor gene which
may have great prognostic value (Shoushtari et al., 2011).
RRM2B and RRM1 have been suggested to be associated with
gemcitabine resistance (Aye et al., 2014) and have been shown
to be overexpressed in a gemcitabine-resistant pancreatic
cancer cell line (Wang et al., 2015).
3.3. Applying the cell line-trained SVM to patient data
Formalin fixed paraffin embedded (FFPE) tissue blocks were
obtained from patients that were treated with paclitaxel and
gemcitabine, and whose response to both drugs are known.
Gene expression measurements for 11 genes from the pacli-
taxel SVM, and gene expression (6 genes) and copy number
(CN; 3 genes) from the gemcitabine SVM were obtained using
qRT-PCR and qPCR (Supplementary Tables 9 and 10). Gene
expression measurements were not obtained for BMF,
CSAG2, SLCO1B3, TWIST1 (paclitaxel), and ABCB1 (gemcita-
bine), as no amplification was observed in these samples by
40 cycles. The absence of amplification in these genes was
related their low levels of expression in breast cancer tissue
(Supplementary Results V e A). In cases where qRT-PCR
showed no amplification for a specific sample out of the genes
measured, the highest cycle run was used as the Ct value for
that gene. Older samples, on average, had lower numbers of
genes with successful measurements (Supplementary
Results V e B).
SVMs were trained using the cell line data with a reduced
set of 11 (paclitaxel e ABCC10, BCL2, BCL2L1, BIRC5, FGF2,
FN1, MAP4, MAPT, NFKB2, TLR6, and TMEM243) and 9 (gemcita-
bine e ABCC10, CMPK1, DCTD, NME1, RRM1, RRM2B, ABCC10-
CN, NT5C-CN, and TYSM-CN) gene values, which corre-
sponded to the measurements obtained from the FFPE tissue
block studies. These SVMs were then applied to the FFPE tis-
sue sample data to predict their sensitivity to paclitaxel and
gemcitabine (see Supplementary Table 11 for full FFPE sample
predictions). The paclitaxel SVM predicted drug sensitivity
with 71% accuracy (Table 1), which was similar to a leave-
one-out analysis on the cell line data, which classified cell
lines with 70.2% accuracy (using the reduced 11-gene subset).
Patients who were treated with docetaxel were excluded from
this summary because the trained SVMonly predicted cell line
response to docetaxel with 57% accuracy (misclassified 19/44,
based on GI50s). Docetaxel and paclitaxel GI50s for all cell
lines were correlated only to a limited extent (R2 ¼ 0.722),
consistent with the possibility that there might potentially
be differences in mechanisms of drug metabolism and resis-
tance between these drugs. The gemcitabine SVM did not
perform as well on the patient sample data as it did on the
cell line leave-one-out analysis, whichwas 79.6% accurate (us-
ing the reduced 9-gene subset). The gemcitabine SVM derived
using binned expression values predicted patient response
with 62% accuracy, however, 72% accuracy was achieved for
samples with gene expression measurements available for
at least 4 of the 6 genes.
Gene expressionmeasurements and clinical datawere also
obtained for 319 patient samples who were treated with pacli-
taxel and anthracycline chemotherapy (Hatzis et al., 2011).
Gene expression data was not available for two genes from
the paclitaxel SVM (BMF and CSAG2), which were two of the
4 genes that could not be measured in the FFPE samples.
Consequently, the same 11-genes used for the FFPE samples
were applied to the data from Hatzis et al., 2011. SVM predic-
tions were compared with the clinical outcome ewhether the
patient had recurrent disease (RD) or complete pathological
response (pCR, see Table 2 for a summary, and
Supplementary Table 12 for all predictions). The SVM pre-
dicted sensitivity in 52 of the 63 patients (84%) that showed
pCR. All patients that showed complete pathological response
exhibited no or minimal residual disease (residual cancer
burden [RCB] class 0/1; Symmans et al., 2007), although
some patients within this subset did not respond to therapy.
This group of patients (RCB 0/1) may derive the greatest
benefit from the paclitaxel SVM analysis. The SVM did not
perform as well in predicting resistance, miscategorizing 135
patients of the 257 with RD (52.5%) as sensitive. However, per-
formance of the SVM exceeded that of the 512-gene signature
Table 1 e Using the SVM to predict patient response from archived
FFPE tissue.
Paclitaxel Gemcitabine
NORM 10 bins NORM 10 bins
No. of accurate
predictions
12 12 9 13
Total 17a 17 21 21
Percent accurate 71% 71% 43% 62%
Odds ratio 5.83 6.00 3.00 3.33
P-valueb 0.1534 0.1534 0.5333 0.3615
a 4 patients were treated with docetaxel instead of paclitaxel, and
were not included in this summary.
b Fisher’s exact test. Gene expression values were either normal-
ized (NORM) or binned into 10 categories (10 bins), as described in
the methods. Please refer to Supplementary Table 11 for all FFPE
clinical response and prediction data.
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described in Hatzis et al., 2011 for both sensitive and resistant
patients. The odds ratio of the 11-gene SVMwas 4.484 (Fisher’s
exact test, p < 0.0001), compared to the odds ratio of 3.181 of
the predictive signature described in that study (Fisher’s exact
test, p < 0.0001).
3.4. Clustering cell line and patient data based on SVM
gene subsets
Two distinct groups emerge from unsupervised clustering us-
ing the SVM gene set for paclitaxel in the cell line data
(Figure 4A). The left cluster (highlighted in light grey) corre-
sponds with the luminal subtype, and the right corresponds
to a mix of basal, claudin-low, and normal-like subtypes.
The proportions of resistant (71% of the left cluster) vs. sensi-
tive (58% of the right cluster) cell lines are not statistically sig-
nificant (c2 ¼ 3.67, 1 degree of freedom, p ¼ 0.056). Cell lines
clustered using the gemcitabine SVM gene expression values
display at least two distinct clusters that do not correspond
to any subtype(s), but, stratify according to gemcitabine sensi-
tivity (73%; left) or resistance (69%; right) (Figure 4B, chi-
statistic ¼ 10.75, p ¼ 0.001, d.f. ¼ 1). Clustering of the FFPE
derived sampleswas not as strong as a consequence of limited
sample numbers and lack of expression measurements for
every gene in every sample (Supplementary Results VI e A).
Nevertheless, clustering of expression in these samples
mirrored the cell line data based on results for MAPT and
BCL2 (for paclitaxel) and DCTD (for gemcitabine).
Unsupervised clustering of expression data from Hatzis
et al. (2011), using the paclitaxel SVM gene set distinguished
patients according to the proportions of those free of distant
relapse (Figure 5 and Supplementary Results VI e B). These
clusters are partially distinguished byMAPT and BCL2 expres-
sion (Figure 5A, the “low MAPT” cluster is indicated in purple,
“high MAPT” in green). MAPT and BCL2 are both components
of the PAM50 Breast Cancer Intrinsic Classifier. Their expres-
sion patterns segregate into luminal and basal subtypes to a
large extent. Low MAPT expressing luminal subtypes were
observed to have significantly worse prognoses than higher
MAPT expressing luminal tumors in the patient dataset
(p < 0.05, Supplementary Results VII). The gene signature
described by Hatzis et al. (2011) predicted treatment “sensi-
tivity” and “insensitivity” accurately within the low MAPT
cluster, where “sensitive” patients exhibit significantly longer
times to distant relapse (Figure 5C, p ¼ 0.0013, log rank test).
However, this was not the case for the high MAPT cluster, as
the proportion free of distant relapse between two predicted
groups did not differ significantly (p ¼ 0.10, log-rank test).
3.5. Significance of SVM classification accuracy
To assess the significance of the derived SVM, we selected
100,000 randomsets of 15 genes froma set of expressionvalues
(to compare to the paclitaxel SVM) and 10 genes from a set of
copy number and expression values (gemcitabine SVM) for
23,030genes. Only 0.14%of paclitaxel and0.01%of gemcitabine
random gene combinations exceeded the classification accu-
racyof thederivedSVMs. (Figure6eA/C). Thehinge loss,which
increasesbasedon themisclassifiedobject’sdistance to thehy-
perplane, was 0.64 for the paclitaxel SVM and 0.66 for the gem-
citabineSVM(optimal is close tozero).Amongtherandomgene
combinations, the likelihood of deriving SVMs with equal or
lower scores was 1.45% and 0.83% for paclitaxel and gemcita-
bine, respectively (Figure 6 e B/D). Thus, the accuracy of the
SVMs achieved for both drugs were not likely due to random
chance (p < 0.05 in all cases, Table 3).
Nearly all of the high performance random gene set combi-
nations appear to be statistical artifacts. Analysis of 10,000
random gene selections found 18 combinations with lower
paclitaxel misclassification response rates. All 18 signatures
were unique (2 transcripts occurred twice) and transcript
combinations were dominated (24%) by alternative splice var-
iants and expressed pseudogenes. None of the random gene
combinations were significantly associated with known bio-
logical pathways. Six of the random signatures contained
10 gene expression values in the patient data. None of these
signatures predicted paclitaxel sensitivity, except one set con-
taining WWP1, which has previously been suggested to be a
prognostic indicator in breast cancer (Nguyen Huu et al.,
2008). This signature (and one based on WWP1 expression
alone) predicted more patients to be sensitive to paclitaxel
(Hatzis et al., 2011) than our derived SVM. Similar numbers
of patients predicted to be sensitive by both SVM models
exhibited complete remission (52 vs. 55), however the
WWP1-based SVM predicted sensitivity in a greater number
of non-responders (n ¼ 178) than our derived SVM (n ¼ 138)
and misclassified 41% of the cell lines. For the gemcitabine
response, the SVM of a single random gene set had a lower
misclassification rate than our derived SVM. The genes in
this set were unrelated to gemcitabine metabolism, with 9 of
10 SVM variables exhibiting copy number changes, two of
which involved non-coding RNA genes.
Table 2 e SVM predictions on 319 patients treated with paclitaxel
from Hatzis et al. (2011).
Cell line 11-gene SVM Hatzis “Rx” prediction
RD pCR RD pCR
All RCB classes
Predicted
insensitive
119 10 186 28
Predicted
sensitive
138 52 71 34
Odds ratio 4.484 3.181
P-valuea <0.0001 <0.0001
RCB class 0/1 only
Predicted
insensitive
11 10 10 28
Predicted
sensitive
19 52 20 34
Odds ratio 3.011 0.6071
P-valuea 0.0359 0.3673
RD ¼ recurrent disease (designated “insensitive” patient response),
pCR ¼ pathological complete response (designated as “sensitive”
patient response), RCB ¼ residual class burden (as described in
Symmans et al., 2007).
a p-values were determined using a Fisher’s exact test. Please refer
to Supplementary Table 12 for all predictions and patient
information.
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Figure 4 e Expression heatmap of the paclitaxel and gemcitabine SVM derived genes for the tested cell lines. Each row represents a gene and each
column a cell line. Red indicates higher expression and blue represents lower expression, as shown by the color bar on the left. ‘Resistant’ cell lines
are colored grey and ‘sensitive’ cell lines are colored white in the row labeled ‘response’. Cell lines are labeled by subtype and copy number according
to the legends. Clustering was done based on the similarity of each cell line’s expression profile in the 1st (column) dimension and each gene’s
expression profile in the 2nd (row) dimension. The dendrograms on the top and left indicate the relatedness of each cell line and gene by the length
and subdivision of the branches, with deeper branches indicating a stronger relationship and branches in the same ’tree’ being more closely related
to each other than data in other ’trees‘. A) A section of the dendrogram for paclitaxel is shaded grey to indicate a cluster composed entirely of
luminal cell lines and a higher proportion of resistant cell lines. The other section is white to indicate a cluster with very few luminal cell lines and
a higher proportion of sensitive cell lines. B) A section of the dendrogram for gemcitabine is shaded grey to indicate a cluster composed of a higher
proportion of resistant cell lines. The other section is white to indicate a cluster with a higher proportion of sensitive cell lines.
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We have developed a online web-based SVM calculator
(http://chemotherapy.cytognomix.com) to predict chemosen-
sitivity from normalized gene expression and copy number
(gemcitabine) values. The user may either input their own
values or populate them from available patient or cell line re-
sults that determined the accuracy of the SVM.
3.6. Translation of signature to other cancer types
To mitigate tissue-specific effects, we rederived SVM models
specific to lung cancer (lung) and hematopoietic and lymphoid
tissue cancer (hematopoietic) cell lines using expression data
from the broad institute (www.broadinstitute.org/ccle/home;
“CCLE_Expression_2012-09-29.res” and “CCLE_NP24.2009_pro-
filing_2012.02.20.csv”). Lung and hematopoietic tissue types
were chosen because they contained the highest number of
cell lines with expression and paclitaxel GI50s. The final
lung SVM contained 14 genes, and classified cell lines with
72% accuracy (Supplementary Results VIII e A). The final he-
matopoietic SVM was composed of 8 genes, and classified
cell lines with 75% accuracy (Supplementary Results VIII e
B). Four genes were present in all three (breast, lung and he-
matopoietic) cancer cell line SVMs (BMF, FGF2, TMEM243,
and TWIST1), and 8 genes were eliminated from all of the
SVMs (ABCB11, BBC3, CNGA3, CYP2C8, CYP3A4, NR1I2, TUBB4A,
and TUBB4B; Supplementary Results VIII e C). MFAs using the
Lung and Hematopoietic SVM gene sets do not show the same
degree of segregation between resistant and sensitive
cell lines as the breast SVM (Supplementary Results VIII e
D/E).
4. Discussion
This paper describes the development of genomic signatures
using support vector machines that can predict breast cancer
tumor response to paclitaxel and gemcitabine. We used a
biologically-driven approach to identify a meaningful group
of genes whose expression levels and copy number may be
useful in guiding selection of specific chemotherapy agents
during patient treatment. Previous studies have derived asso-
ciations between the genomic status of one ormore genes and
tumor response to certain therapies (Duan et al., 2003; Glinsky
et al., 2005; Hatzis et al., 2011; Ma et al., 2004; Rajput et al.,
2013; van’t Veer et al., 2002). Correlations between single
gene expression and tumor resistance (Duan et al., 2003,
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Figure 5 e A) Expression heatmap of the paclitaxel SVM derived genes for 319 tumor samples (Hatzis et al., 2011). See Figure 4 for heat map
labeling and diagram details. A section of the dendrogram on the top is shaded purple to indicate a cluster of tumors (63% basal) with a
significantly worse outcome assessed by the proportion free of distant relapse curves (shown in B). Another section is shaded green (83% luminal)
with significantly better outcomes. The cluster shaded gray (22% basal, 53% luminal) can be clustered independently with similar stratification by
subtype and outcome (Supplemental Information VI). C) The Hatzis et al., 2011 gene signature performs very well in the purple cluster and poorly
in the green, based on the KaplaneMeier curves constructed on each subset using their published labels (“insensitive” and “sensitive”).
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1999) do not take into account multiple mechanisms of resis-
tance or assess interactions between multiple genes. ABC
transporter overexpression has long been shown to confer
resistance, but enzymatic or functional inhibition has not sub-
stantially improve patient response to chemotherapy
(Samuels et al., 1997).
Multi-gene analytical approaches have previously been
successful in deriving prognostic gene signatures for metasta-
tic risk stratification (Oncotype DX, MammaPrint), subtypes
(PAM50), and efforts have beenmade to predict chemotherapy
resistance (Hess et al., 2006; Hatzis et al., 2011). Given the
complexity of genomic changes and the fundamental
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Figure 6 e The fraction of cell lines misclassified (A/C) and hinge loss scores (B/D) were measured on SVMs derived using randomly selected gene
sets. 15-gene (to compare to the paclitaxel SVM, A/B) or 10-gene (to compare to the gemcitabine SVM, C/D) values were randomly selected from
an initial set of 23,030 genes and used to derive SVMs. The performance of 100,000 iterations of the random signatures are plotted in the above
histograms. The hinge loss scores for the paclitaxel and gemcitabine final SVM gene subsets lie in the lowest 2nd (paclitaxel, z-score L2.0,
p< 0.05 one-sided) and 1st percentiles (gemcitabine, z[ L2.16, p< 0.05) of the data. Expression alone was used for the 15-gene sets (A/B).
Copy number and expression were used for the 10-gene sets (C/D). The red arrow heads indicates where the optimized paclitaxel and gemcitabine
SVM gene signatures are found in the distribution.
Table 3 e SVM performance using randomly selected genes based off 100,000 iterations.
Minimum Maximum Average Standard
deviation
Drug SVM z-score p-value No. random
SVM  drug SVMsa
Percent misclassification of cell lines in leave-one-out analysis
15-geneb 12.2% 83.7% 42.7% 8.8% 18.4% 2.78 0.0027 141
10-genec 12.2% 90.2% 48.0% 10.5% 15.9% 3.06 0.0011 10
Hinge loss score
15-gene 0.39 1.66 0.93 0.14 0.64 2.04 0.0207 1453
10-gene 0.30 2.02 1.05 0.18 0.66 2.16 0.0153 826
Misclassification rates and hinge loss scores were determined from SVMs derived using 100,000 random combinations of gene expression and
copy number values from 23,0303 genes. The minimum, maximum, average, and standard deviations of each 100,000 iterations were deter-
mined, and compared to the pacliataxel and gemcitabine SVMs (“drug SVM”).
a The number of random gene combinations with equal or lower misclassification rates or hinge loss scores compared to the drug SVMs.
b Random selection of 15 gene expression values were compared to the paclitaxel SVM.
c Random selection of 10 gene expression or copy number values were compared to the gemcitabine SVM.
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biological differences among the intrinsic subtypes of breast
cancer (Cancer Genome Atlas Network, 2012; Dorman et al.,
2014), this approach has advantages over analysis of isolated
genes. Reasonable gene signatures associatedwith breast can-
cer outcome can be obtained by chance alone (Venet et al.,
2011), however our results show that such signatures are
especially rare. Gene signatures derived without reference to
the underlying mechanisms of chemotherapy response do
not capture meaningful biological results (Drier and Domany
2011).
Our approach started with a focused biologically-relevant
initial gene set, rather than taking a genome-wide approach.
The derived signatures were demonstrated to significantly
outperform random selected combinations of genes in predic-
tion of sensitivity and resistance. The random gene sets may
be statistical artifacts, as they were not enriched for any bio-
logical relevant pathways, and included expressed pseudo-
genes. The compositions of these other gene sets were
distinct from the set used to derive the SVM and another 20-
gene signature for taxane sensitivity (He et al., 2014).
Our analysis highlights the importance of the expression of
genes encoding microtubule-associated proteins and
apoptotic regulators in paclitaxel resistance (McGrogan
et al., 2008; Tanaka et al., 2009; Wang et al., 2013). MAPT
expression was significantly correlated with drug resistance,
and both MAPT and MAP4 were components of the optimized
paclitaxel SVM gene set. In clustering analysis of both cell
lines and patients, MAPT was differentially expressed be-
tween tumor clusters stratified by subtype and outcome
(Figures 4 and 5). Our results confirm that apoptosis-related
proteins, particularly BCL2L1, but also BCL2, BMF, and BIRC5,
contribute to paclitaxel sensitivity (Flores et al., 2012).
BCL2L1, BCL2 and BMFwere found to be stable in breast cancer
tumors, reinforcing the notion that alterations in stable genes
contribute to drug resistance (Park et al., 2012).
Supplementary Table 13 describes genes analyzed in the
context of their biological pathways and relevant literature.
The gemcitabine metabolic pathway has been well charac-
terized (Alvarellos et al., 2014), however the critical genes have
not been treated as an ensemble in conferring resistance (see
Supplementary Table 14 for interpretation of the MFA results
for all genes). The MFA analyses indicated gemcitabine genes
predominately contribute to drug resistance through overex-
pression. For DCTD, however, underexpression is associated
with increased resistance in the MFA analysis. DCTD defi-
ciency causes an imbalance in the dNTP pool (Eriksson et al.,
1984), which affects control of DNA replication. DCTD is
inhibited by dFdCTP (a gemcitabine metabolite) through a
mechanism by which gemcitabine exhibits self-potentiation
(the reduction of competing natural metabolites) (Xu and
Plunkett, 1992). LowerDCTD expression and as a consequence,
activity, would reduce gemcitabine self-potentiation by
altering the dNTP pool. This state is related to drug resistance,
whichwas noticeably lower in 4 cell lineswith increased resis-
tance (HCC1187, HCC1428, HCC202, and MDAMB134VI). Like
DCTD, CDA also catalyzes the conversion of gemcitabine
monophosphate to difluorodeoxyuridine monophosphate
(Figure 2B), and accounts for 90% of this conversion in the
cell (Govindarajan et al., 2009). However, drug resistance was
associated with CDA overexpression. Likewise, the
ribonucleotide reductase subunits RRM1 and RRM2Bmake sig-
nificant contributions to the gemcitabine SVM. The RRM1-
RRM2B complex is associated with mitochondrial genomic
integrity (Bourdon et al., 2007) and RRM2B is necessary for
nucleotide synthesis in DNA repair (Kuo et al., 2012). Changes
in RRM2B expression could be associated with mitochondrial
dysfunction, or may result from loss of p53 expression, which
usually induces RRM2B expression (Tanaka et al., 2000).
The 11-gene paclitaxel SVM was able to classify FFPE pa-
tient samples we obtained and measured in our lab with
similar accuracy to that of the cell lines. In addition, the
same SVM model was able to predict complete pathological
response on a second patient data set, with greater accuracy
than the originally reported gene signature (Hatzis et al.,
2011). The SVM performed particularly well for predicting
drug-sensitive tumors with low or no minimal residual dis-
ease (Table 2). The SVM gene signature proved to be resilient
as a diagnostic marker, as the performance was not compro-
mised by the lack of expression data for 4 genes.
Unlike paclitaxel, gemcitabine was not used to treat pa-
tients in the study by Hatzis et al. (2011) or other publically
available data sets. The SVM analysis on RNA expression
and DNA copy number from the FFPE-derived tumor punches
appeared to predict response more accurately when expres-
sion values were obtained for the majority of genes in the
SVM. Obtaining high quality gene expression measurements
from FFPE samples was especially difficult from older tissue
blocks (Supplementary Results V e B) as previously noted
(Choudhary et al., 2014). Consequently, the SVM analysis
may be better suited for fresh-frozen tumor tissue or more
sensitive gene expression analyses (such as mRNA
sequencing). Missing data appeared to impact the gemcita-
bine SVM to a greater extent than the paclitaxel SVM, which
may be due to the smaller number of gene measurements
required for this SVM.
Including gene expression subtype in the SVM did not
improve the classification accuracy even though subtype is
known to contribute to tumor biology (Heiser et al., 2012).
However, the two paclitaxel PAM50 genes (MAPT and BCL2)
partially stratify the cell lines by subtype during unsupervised
clustering (Figure 5). This is not the case in the gemcitabine
gene set. In patient data, clustering by expression of the
SVM genes also revealed statistically significant deterioration
in outcome for low MAPT expressing luminal tumors
(Supplementary Information VII).
Machine learning may be a fruitful approach in the selec-
tion of other chemotherapy agents. Translating our results
to the assessment of human tumor samples (Ga˛sowska-
Bodnar et al., 2014) confirmed our gene signature’s relevance
to predicting chemoresistance by SVM. However, both SVMs
were not integrated because cell lines were treated with indi-
vidual drugs, so predicting whether patient response to these
drug interactions will be synergistic or antagonistic is difficult
with our approach. In addition, while pointmutations are well
known contributors to chemoresistance of other drugs, this
approach e for either SVM training or testing e is not condu-
cive for prediction of chemosensitivity given the sparse num-
ber of observations for these types of mutations.
In cases without residual disease, the paclitaxel SVM was
particularly effective in predicting which tumors would
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 8 5e1 0 096
show complete pathological response. Docetaxel is prescribed
somewhat interchangeably (Crown et al., 2004; Hatzis et al.,
2011; O’Shaughnessy et al., 2013) and both paclitaxel and
docetaxel act through similar biological pathways (Oshiro
et al., 2009). However, the performance of the paclitaxel SVM
on patients treated with docetaxel was reduced. This SVM
contains 8 paclitaxel resistance genes. Predictions of doce-
taxel sensitivity might be improved by rederiving a specific
SVM using taxane pathway genes (Oshiro et al., 2009), and
those known to be associated with resistance to doclitaxel
(such as CYP1B1 (Chang et al., 2015; Cui et al., 2015), miR-141
or EIF4E (Yao et al., 2015), DKK3 (Tao et al., 2015), ABCB1
(Hansen et al., 2015; Kato et al., 2015), BIRC5 (Ghanbari et al.,
2014), ABCC10 (Domanitskaya et al., 2014), miR-452 (Hu et al.,
2014), and PAWR (Pereira et al., 2013)). The approach that we
have introduced could aid in rational selection of other thera-
peutic regimens that evade or at least minimize the effects of
chemoresistance.
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